also note: secondary link source including professional commentary
Abstract:
Purpose: Preclinical studies have suggested accelerated
tumor growth, local invasion, and distant metastasis after withdrawal of
treatment
with some antiangiogenic agents. To investigate
whether discontinuation of bevacizumab treatment is associated with
accelerated
disease progression or increased mortality, we
retrospectively analyzed five randomized, placebo-controlled phase III
studies
in 4,205 patients with breast, colorectal,
renal, and pancreatic cancer.
Conclusion This
retrospective analysis of five placebo-controlled clinical trials does
not support a decreased time to disease progression,
increased mortality, or altered disease
progression pattern after cessation of bevacizumab therapy.
Footnotes
-
Supported in part by F. Hoffmann-La Roche, Basel, Switzerland.
-
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
-
Clinical trial information can be found for the following:
NCT00738530.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.